Industry Payments Common for Physician Peer Reviewers of Top Journals
Peer reviewers in this study received $64.18 million in general payments between 2020 and 2022
Risk for Second Melanoma Up for Those With First Melanoma Diagnosis
Melanoma less common among racial and ethnic minorities, but they still have increased rate of second primary melanoma
Bimekizumab Safe, Efficacious Over Two Years for Hidradenitis Suppurativa
Clinically meaningful efficacy outcomes observed at one year maintained to two years of treatment
Long-Term Efficacy for Lebrikizumab Seen in Moderate, Severe Eczema
Long-term efficacy seen for lebrikizumab every two weeks or every four weeks in moderate-to-severe atopic dermatitis
Female Residents Underrepresented in High-Compensation Specialties
High-compensation surgical specialties experienced increase in the proportion of female applicants and matriculants from 2008 to 2022
Anti-CTAg Antibodies Identified in Stage I, II Melanoma
Specific antibodies against three tumor antigens identified as promising diagnostic biomarkers for early-stage melanomas
Home-Based Phototherapy as Effective as Office-Based for Psoriasis
For plaque or guttate psoriasis, home-based phototherapy noninferior to office-based phototherapy for PGA and DLQI
Melanoma Risk Increased After Radioactive Iodine Treatment for Primary Thyroid Cancer
Standardized incidence ratios elevated for all nonkeratinocyte skin cancers, melanoma
Semaglutide Beneficial for Hidradenitis Suppurativa in Patients With Obesity
Semaglutide added to standard treatments yields improvement in quality of life, reduction in flares
Long-Term Survival Benefit Seen for Nivolumab in Advanced Melanoma
Continued survival benefit seen for nivolumab plus ipilimumab and for nivolumab monotherapy versus ipilimumab monotherapy
